Enovis Lifts Full-Year EBITDA and EPS Outlook, Doubles Buyback to $200M
ENOV sits 46% above its 52-week low of $16.7 on elevated volume (2.4× avg).
Summary
Enovis posted Q3 net sales of $559M, up 2% reported and 5% organic, with net income of $3M and adjusted EPS of $0.88. Management raised full-year adjusted EPS to $3.58-$3.79 from $3.52-$3.73 and adjusted EBITDA to $428-$438M from $425-$435M, while narrowing revenue to $2.32-$2.35B with 5% organic growth expected. The board authorized up to $200M of buybacks, replacing the prior $100M authorization. The guidance raise is modest in dollar terms but the doubled repurchase capacity is a meaningful step for a company this size, and it comes after the September binding offer for eCential Robotics and open-market insider buying by the CEO and CAO in the $19-$20 range. Watch whether repurchases actually get executed and whether the raised outlook holds through Q4.
At the time of this announcement, ENOV was trading at $24.35 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $16.70 to $32.41. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.